SEGOVA represent the third level of ovarian rejuvenation therapy, integrating tissue-based regenerative techniques alongside stem cells and bioactive factors to restore ovarian function with the highest level of precision and effectiveness.

 

The SEGOVA procedure was first developed in 2016 as an all-encompassing medical biological procedure designed to rejuvenate and enhance ovarian function.

In 2022/2023 it was further refined, evolving into a more streamlined, next-generation advancement of the original SEGOVA method. This progress was made possible through advanced surgical techniques in tissue re-transplantation and the incorporation of innovative scaffolds. The latest iteration of the SEGOVA procedure offers a shorter hospital stay (only one to two days) and improved precision in visual control during tissue and stem cell re-transplantation.

Active principles in SEGOVA:

1. hcPRP - Activated autologous highly concentrated platelet growth factors (hcPRP)
2. BRF - Activated autologous bio-regenerative fibrin (BRF)
3. BM mSC - Mesenchymal bone marrow stem cells (bm mSC)
4. IVA - In Vitro Activated (IVA) ovarian tissue
5. Metabolic and physical optimisation - Patient's participation in metabolic optimization and specific training.

SEGOVA procedure consists of the following:

1. Preparation:

• one or more days or weeks of preparation, including analyses of hormones, immunological status, infections, metabolism, vitamins, microelements and genetics.

 
2. Performing of SEGOVA Procedure:

• a single or a two-day stay in the hospital, general anaesthesia

• blood is drawn from the patient to isolate and concentrate autologous PRP with BRF (fully automatized closed system) and autologous thrombin.

• biopsy of the iliac bone and aspiration of the bone marrow

• separation and processing of mSC from the bone marrow aspirate concentrate (fully automatized closed system)

• minimally invasive laparoscopic surgery with tangential ovarian cortex excision.

• administration of autologous activated haemostatics BRF instead of classical destructive surgical techniques

• IVA - micro-fragmentation of ovarian tissue submerged in mediums with autologous activated hcPRP

• creation of subcortical tunnels for the IVA ovarian cortical tissue and mSC re-transplantation

• application of autologous activated BRF scaffold in the adequate subcortical tunnels

• application of the micro fragmented IVA ovarian cortical tissue with mSC and autologous activated hcPRP into the adequate subcortical spaces

• closure of the tunnels and re-creating the ovarian surface with the activated autologous BRF.

• control of haemostasis

• discharge from the hospital in 1 or 2 days.

 
3. The additional activities:

• the Nutritionist for Metabolic Optimisation and the physiotherapist gonadal HIIT program.

 
4. Reproductive follow-up:

• regular ultrasound and laboratory follow-up, with suggestions or implementation of advanced in vitro fertilisation techniques.

SEGOVA is a biological regenerative therapy which has been done in several hundreds of patients. Hormonal outcome - the success of SEGOVA in endocrine terms was in 85% of patients, in terms of improving hormone levels (AMH, FSH, LH, E2, Pg) up to 30%, which lasted over 2 years.

From a reproductive point of view - the appearance of follicles had 61% of patients, eggs in 24%, and embryos in 17% of patients. Pregnancy was achieved in 15% of the monitored patients, and 10% had childbirth. *

* Not the final results, as 23 vitrified embryos (out of 71 obtained) have not been transferred.​

Learn more about the breaking new technology within the ovarian rejuvenation, created by professor Aleksandar Ljubić: